Table 1 Univariate and multivariate analysis of predictors of SVR12 in treated patients

 Mean ± SD

55.05 ± 8.13

57.8 ± 7.29

0.22

1.0(0.97-1.13)

 (Min–Max)

(36–69)

(41–70)

 Male

31 (33.7%)

9(60%)

0.06

2.9(0.96-9.05)

 Female (r)

61 (66.3%)

6(40%)

1

 Naïve

72 (78.3%)

12(80%)

0.88

0.9(0.23-3.5)

 Experienced (r)

20 (21.7%)

3(20%)

1

 Male: (13.2–17.5 gm/dl)

12.17 ± 1.6

12.02 ± 1.57

0.75

0.9(0.67–1.33)

 Female: (11.5–16 gm/dl)

1

WBCs *10³/m(4 11 × 10³/ml)

4.66 ± 1.6

3.75 ± 1.49

0.05

0.66(0.44–1)

1

0.04

0.64 (0.42–0.98)

Platelet count × 10³/ml (150–450 × 10³/ml)

94.5 (50–356)

84 (55–142)

0.16

0.99 (0.97–1.004)

PCR (iu/ml)*10³

297.10 (0.135–20223)

437 (9.97–4823)

0.36

1.0 (1.0–1.0)

ALT/ULN (fold)

1.325 (0.22–5.35)

0.98 (0.48–4.12)

0.35

0.66 (0.27–1.58)

AST/ULN (fold)

1.765 (0.4–5.85)

1.73 (0.4–4.7)

0.94

0.98 (0.59–1.64)

Serum Albumin (g/dl) (3.4–5.4 g/dl)

2.8 ± 0.4

2.79 ± 0.26

0.31

0.45(0.09–2.09)

Serum bilirubin (mg/dl) (0.3–1 mg/dl)

1.42 ± 0.7

1.74 ± 0.87

0.15

1.68 (0.84–3.39)

I.N.R. (0.9–1.2)

1.32 ± 0.22

1.34 ± 0.18

0.60

1.93 (0.1623.2)

 Male: (0.6–1.2 mg/dl)

0.85 ± 0.25

0.99 ± 0.41

0.07

4.6 (0.88–23.8)

 Female: (0.8–1.4 mg/dl)

AFP (μg/l) (< 8 μg/l)

12.35 (0.1–201)

9 (2.64–83)

0.4

0.98(0.96–1.02)

 Mean ± SD

11 ± 2.97

12.87 ± 2.6

 (Min-max)

(6–17)

(8–18)

 < 10(r)

29 (31.5%)

2(13.3%)

0.15

1

 ≥ 10

63 (68.5%)

13(86.7%)

2.9(0.63–14.1)

 Liver cirrhosis

92 (100%)

15(100%)

1

Undefined

 Splenomegaly

55 (59.8%)

6(40%)

0.2

0.45(0.15–1.4)

 Ascites

44 (47.8%)

11(73.3%)

0.07

3.0(0.89–10.1)

 Hemangioma

0 (0%)

1(6.67%)

0.15

U`ndefined

 Ablated HCC

1 (1.09%)

0(0%)

1.0

Undefined

 B7

67 (72.8%)

6(40%)

0.18

1

1

 B8

20 (21.7%)

6(40%)

0.06

3.4(0.97–11.5)

0.07

3.2(0.9–11.6)

 B9

5 (5.4%)

3(20%)

0.024

6.7(1.3–35.1)

0.016

8.6(1.5–49.8)